ZhangY.F., YangX., ZhangY.J., SunY.L., ZouX.L., KongQ.Y.Peroxisome proliferator-activated receptor-gamma is expressed by rat peritoneal mesothelial cells: its potential role in peritoneal cavity local defense.Am J Nephrol2006; 26: 602–11.
6.
YoshimotoT., NaruseM., NishikawaM., NaruseK., TanabeA., SekiT.Anti-hypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.Am J Physiol1997; 272: E989–E996.
7.
VermaS., BhanotS., ArakawaE., YaoL., McNeillJ.H.Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats.Pharmacology1998; 56: 7–16.
8.
NishimotoY., TomidaT., MatsuiH., ItoT., OkumuraK.Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats.Hypertension2002; 40: 190–4.
9.
KhanO., RiaziS., HuX., SongJ., WadeJ.B., EcelbargerC.A.Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone.Am J Physiol2005; 289: F442–F450.
10.
ArimaS., KohaguraK., TakeuchiK., TaniyamaY., SugawaraA., IkedaY.Biphasic vasodilator action of troglitazone on the renal microcirculation.J Am Soc Nephrol2002; 13: 342–9.
YosefyC., MagenE., KiselevichA., PrilukR., LondonD., VolchekL.Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.J Cardiovasc Pharmacol2004; 44: 215–22.
13.
NegroR., MangieriT., DazziD., PezzarossaA., HassanH.Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.Diabetes Res Clin Pract2005; 70: 20–5.
14.
SarafidisP.A., LasaridisA.N., NilssonP.M., MouslechT.F., Hitoglou-MakedouA.D., StafylasP.C.The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.Metabolism2005; 54: 1236–42.
PistroschF., HerbrigK., KindelB., PassauerJ., FischerS., GrossP.Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.Diabetes2005; 54: 2206–11.
17.
RuilopeL.M., BakrisG.L., McMornS.O., WestonW.M., HuangC., HeiseM.A.Rosiglitazone added to metformin reduces urinary albumin/creatinine ratio and ambulatory blood pressure in subjects with microalbuminuria and type 2 diabetes [Abstract].Diabetologia2005; 48(Suppl 1): A283.
18.
MarxN., SchonbeckU., LazarM.A., LibbyP., PlutzkyJ.Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.Circ Res1998; 83: 1097–103.
19.
MarxN., BourcierT., SukhovaG.K., LibbyP., PlutzkyJ.PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.Arterioscler Thromb Vasc Biol1999; 19: 546–51.
20.
WakinoS., HayashiK., TatematsuS., HasegawaK., TakamatsuI., KandaT.Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.Hypertens Res2005; 28: 255–62.
21.
WalkerA.B., NaderaliE.K., ChattingtonP.D., BuckinghamR.E., WilliamsG.Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.Diabetes1998; 47: 810–14.
22.
RicoteM., LiA.C., WillsonT.M., KellyC.J., GlassC.K.The peroxisome proliferator-γ activated receptor is a negative regulator of macrophage activation.Nature1998; 391: 79–82.
23.
JiangC., TingA.T., SeedB.PPAR-γ agonists inhibit production of monocyte inflammatory cytokines.Nature1998; 391: 82–6.
24.
GumieniczekA.Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits.Life Sci2003; 74: 553–62.
25.
MajithiyaJ.B., ParmarA.N., TrivediC.J., BalaramanR.Effect of pioglitazone on L-NAME induced hypertension in diabetic rats.Vascul Pharmacol2005; 43: 260–6.
MaedaA., HorikoshiS., GohdaT., TsugeT., MaedaK., TominoY.Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)-gamma.Cell Biol Int2005; 29: 422–8.
28.
SidhuJ.S., CowanD., KaskiJ.C.The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.J Am Coll Cardiol2003; 42: 1757–63.
29.
DongF.Q., LiH., CaiW.M., TaoJ., LiQ., RuanY.Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats.Chin Med J2004; 117: 1040–4.
30.
ZafiriouS., StannersS.R., PolhillT.S., PoronnikP., PollockC.A.Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses.Kidney Int2004; 65: 1647–53.
31.
OnozakiA., MidorikawaS., SanadaH., HayashiY., BabaT., KatohT.Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione.Biochem Biophys Res Commun2004; 317: 24–9.
32.
XiongZ., HuangH., LiJ., GuanY., WangH.Anti-inflammatory effect of PPARgamma in cultured human mesangial cells.Ren Fail2004; 26: 497–505.
33.
UetaM., WakisakaM., AgoT., KitazonoT., NakamuraU., YoshinariM.PPARgamma ligands attenuate mesangial contractile dysfunction in high glucose.Kidney Int2004; 65: 961–71.
34.
GrudenG., SettiG., HaywardA., SugdenD., DugganS., BurtD.Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone.J Am Soc Nephrol2005; 16: 688–96.
35.
WongT.Y., SzetoC.C., ChowK.M., LeungC.B., LamC.W.K., LiP.K.T.Rosiglitazone (RSG) reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients on peritoneal dialysis.Am J Kidney Dis2005; 46: 713–19.
36.
van HoolandS., BoeyO., Van der NiepenP., Van den BrandenC., VerbeelenD.Effect of short-term rosiglitazone therapy in peritoneal dialysis patients.Perit Dial Int2009; 29: 108–11.
37.
SongJ., KnepperM.A., HuX., VerbalisJ.G., EcelbargerC.A.Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats.J Pharmacol Exp Ther2004; 308: 426–33.
38.
ZhangH., ZhangA., KohanD.E., NelsonR.D., GonzalezF.J., YangT.Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.Proc Natl Acad Sci U S A2005; 102: 9406–11.
39.
PengY., LiuH., LiuF., LiuY., LiJ., ChenX.Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.Nephrology (Carlton)2006; 11: 516–23.
40.
YaoQ., AyalaE.R., QianJ.Q., StenvinkelP., AxelssonJ., LindholmB.A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells.Clin Nephrol2007; 68: 295–301.
41.
NissenS.E., WolskiK.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med2007; 356: 2457–71.
